



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  C07D 473/40	A1	(11) International Publication Number: WO 93/15075  (43) International Publication Date: 5 August 1993 (05.08.93)
(21) International Application Number: PCT/GB93/00185  (22) International Filing Date: 28 January 1993 (28.01.93)		(74) Agent: JONES, Pauline; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).
(30) Priority data: 9201961.1 30 January 1992 (30.01.92) GB		(81) Designated States: AU, CA, JP, KR, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant ( <i>for all designated States except US</i> ): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  (72) Inventor; and (75) Inventor/Applicant ( <i>for US only</i> ) : KILLEN, Christopher, Robert, James [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, West Sussex BN14 8QH (GB).		Published <i>With international search report.</i>

(54) Title: PREPARATION OF 2-AMINO-6-CHLOROPURINE

## (57) Abstract

A process for preparing 2-amino-6-chloropurine comprises reacting a 2,9-diacylated derivative of guanine with a chlorinating agent in the presence of a phase transfer catalyst containing chloride ions, and thereafter removing the 9-acyl group and the 2-acyl group by hydrolysis.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

**Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.**

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BC	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MC	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

-1-

### Preparation of 2-amino-6-chloropurine

This invention relates to a process for the preparation of a compound useful  
5 as an intermediate in the preparation of pharmaceutical compounds.

The compound 2-amino-6-chloropurine of formula (I):



10

(I)

is a useful intermediate in the preparation of nucleoside analogue antiviral agents, such as penciclovir and famciclovir, described in EP-A-141927 (Example 1) and EP-A-182024 (Example 2). The intermediate is  
15 9-substituted with an appropriate side chain precursor, followed by conversion of the 6-chloro moiety to a hydroxy (a guanine) or hydrogen (a 2-aminopurine).

EP-A-203685 (Beecham Group p.l.c.) describes a process for preparing a  
20 compound of formula (I) as hereinbefore defined, which process comprises reacting guanine with a chlorinating agent in the presence of a phase transfer catalyst containing chloride ions. EP-A-433846 (Hoechst Aktiengesellschaft) describes a corresponding process for preparing the 2-acylated derivative, involving chlorination of 2,9-diacylguanine and subsequent removal of the 9-  
25 acyl group by hydrolysis.

The reaction is preferably carried out in a polar inert organic solvent such as acetonitrile, tetrahydrofuran, dioxan, nitromethane, diglyme, dimethoxyethane, or dichloromethane. Acetonitrile is highly preferred.

30

-2-

Suitable phase transfer catalysts include tetrasubstituted ammonium chlorides. Examples of ammonium substituents include C<sub>2</sub>-12 alkyl, usually C<sub>2</sub>-4 alkyl, or phenyl or benzyl. Other possible phase transfer catalysts include tetra-substituted phosphonium chlorides wherein examples of the substituents are as defined above for ammonium chlorides. Preferably the phase transfer catalyst is tetraethylammonium chloride.

The phase-transfer catalyst is preferably present in an amount of from 1 to 3 equivalents of the compound of formula (II) and preferably from 1 to 2 equivalents.

A preferred chlorinating agent is phosphorus oxychloride.

Preferably the chlorinating agent is present in an amount of from 2-10 molar equivalents of the guanine derivative.

The reaction may be effected in the presence of a weak base, such as a tertiary amine, for example N,N-dimethylaniline or diethylaniline or triethylamine. The base is usually present in an approximately molar equivalent amount with respect to the guanine derivative. Alternatively, a catalytic amount of water may be added to the reaction mixture. When acetonitrile is the solvent, added base may not be necessary, but is preferred.

The reaction is preferably carried out at an elevated temperature of from 30-100°C, most preferably under reflux and/or with ultrasonication at 50-70°C.

Preferably the reaction is allowed to proceed for a period of greater than half an hour, usually less than 30 hours.

We have now discovered that the compound of formula (I) may be prepared from 2,9-diacylguanine.

-3-

Accordingly, the present invention provides a process for preparing 2-amino-6-chloropurine, which process comprises reacting a 2,9-diacylated derivative of guanine with a chlorinating agent in the presence of a phase transfer catalyst containing chloride ions, and thereafter removing the 9-acyl group and the 2-acyl group by hydrolysis.

The reaction is described in EP-A-203685 and EP-A-433846, which are incorporated herein by reference, except that methyltriethylammonium chloride is a preferred phase transfer catalyst; the amount of phosphorus oxychloride may be reduced to 2-4 equivalents, and the reaction time can be reduced.

If the removal of the 9-acyl group generally occurs at ambient temperature (below 30°C), but higher temperatures and reaction times (80-100°C, 1-2 hours) are needed for removal of the 2-acyl group. Aqueous sodium hydroxide is a suitable basic medium for the hydrolysis.

The following example illustrates the invention.

20

#### Example

Diacetyl guanine (8.0g, 0.034 moles), triethylmethylammonium chloride (15.45g, 0.102 moles), and triethylamine (4.74 mls, 0.034 moles) were heated together with stirring in acetonitrile (70mls) to 50°C. Phosphorus oxychloride (6.34 mls, 0.068 moles) was then added and stirring continued for 4 hours. The reaction mixture was cooled and then added to aqueous sodium hydroxide solution (20g in 300mls water). The reaction mixture was heated to 80°C for 2 hours and then the volume made up to 300 mls with water. The mixture was cooled to 25°C and the pH adjuster to 7 using 10% hydrochloric acid. The resulting slurry was stirred for fifteen minutes and the product filtered off and washed with water 30 mls and then dried at 80°C under vacuum to give a cream/off white coloured product.

35 Weight 2-amino-6-chloropurine 4.69 g (74.6% yield).

-4-

**Claims**

1. A process for preparing 2-amino-6-chloropurine, which process comprises reacting a 2,9-diacylated derivative of guanine with a chlorinating agent in the presence of a phase transfer catalyst containing chloride ions, and thereafter removing the 9-acyl group and the 2-acyl group by hydrolysis.
2. A process according to claim 1, as described in EP-A-203685 and EP-A-433846.
- 10 3. A process according to claim 2, wherein the chlorinating agent is phosphorus oxychloride and the phase transfer catalyst is methyltriethylammonium chloride.
- 15 4. A process according to in claim 3, wherein the amount of phosphorus oxychloride is 2-4 equivalents with respect to the 2,9-acylated guanine.
5. A process according to claim 1, wherein aqueous sodium hydroxide is used as the basic medium for the hydrolysis.
- 20 6. A process according to claim 1, substantially as described herein with reference to the Example.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 93/00185

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D473/40

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	C07D

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	EP,A,0 433 845 (HOECHST) 26 June 1991 *Complete specification* ---	1-6
A	EP,A,0 203 685 (BEECHAM) 3 December 1986 cited in the application *Complete specification* ---	1-6
A	EP,A,0 433 846 (HOECHST) 26 June 1991 cited in the application *Complete specification* ---	1-6
P,A	WO,A,9 213 859 (SMITH-KLINE BEECHAM) 20 August 1992 *Complete specification* -----	1-6

<sup>10</sup> Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

<sup>11</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<sup>12</sup> X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step<sup>13</sup> Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

&amp; document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

21 APRIL 1993

Date of Mailing of this International Search Report

13. 05. 93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

LUYTEN H.W.

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

GB 9300185  
SA 69726

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 21/04/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0433845	26-06-91	DE-A-	3941658	20-06-91
EP-A-0203685	03-12-86	AU-B-	589612	19-10-89
		AU-A-	5501286	25-09-86
		CA-A-	1273337	28-08-90
		DE-A-	3681500	24-10-91
		JP-A-	61227583	09-10-86
		US-A-	4736029	05-04-88
EP-A-0433846	26-06-91	DE-A-	3941657	20-06-91
		JP-A-	4234883	24-08-92
WO-A-9213859	20-08-92	AU-A-	1185892	07-09-92

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.